Cutaneous manifestations in chronic myeloid leukemia in chronic phase treated with imatinib.

It was concluded that imatinib is associated with many adverse cutaneous side effects which should be overcome or reduced by either decreasing the duration of treatment with imatinib or switching to other treatment options.